Heterogeneous expression of A33 in colorectal cancer: possible explanation for A33 antibody treatment failure

Author(s)

Baptistella, Antuani R. ; Salles Dias, Marcos Vinicios ; Aguiar, Jr., Samuel ; Begnami, Maria D. ; Martins, Vilma R.

• Document type: Journal article
• Source: ANTI-CANCER DRUGS; v. 27, n. 8, p. 734-737, SEP 2016.
• Web of Science Citations: 2

Abstract

The A33 protein, expressed in colorectal tumors, is a target for improving treatment of patients with colorectal cancer. Over the last decade, studies have tested anti-A33 antibody as a therapeutic agent for these patients. Preclinical results were promising, but clinical trials did not confirm positive results. Here, immunohistochemistry in colorectal cancer tissue showed that samples from well-differentiated tumors presented a strong A33 membrane staining, whereas poorly differentiated tumors and mucinous adenocarcinomas showed weak cytoplasmic and nuclear staining. Moderately differentiated tumors presented variable staining. We suggest that in future clinical trials, patients should be selected on the basis of membrane expression of A33. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved. (AU)

• FAPESP's process: 13/04913-0 - Identification and characterization of the extracellular vesicles secreted by rectal cancer and their relation with the response to neoadjuvant treatment
• Grantee: Antuani Rafael Baptistella
• Support Opportunities: Scholarships in Brazil - Doctorate
• FAPESP's process: 09/14027-2 - Mechanisms associated with the function of prion protein and its ligand STI1/Hop: therapeutic approaches
• Grantee: Vilma Regina Martins
• Support Opportunities: Research Projects - Thematic Grants